...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: At least RVX has a shorter trial timeline than ESPR

Just following up on my last rambling post.

What I was trying so say at the end of my last post is that perhaps the multiple pathway effects (Pathways affected include complement cascade, acute phase response, coagulation/fibrin clotting cascade, inflammation and calcification.) caused by apabetalone are so remarkable that scientists, investors and BP do not believe it?

Perhaps this is where doubt resides? But this information has been proven.

Had to get that out of my head.

Cheers

Toinv

Share
New Message
Please login to post a reply